InsiderTrades

Form 4 for AGIO AGIOS PHARMACEUTICALS, INC.

Accepted 2026-01-02 00:00:00 ET · period of report 2025-12-30 · accession 0001439222-26-000002 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-01-02 2025-12-30 AGIO Jones Cecilia CFO S - Sale+OE $27.09 -2,932 37.4K -7% -$79.4K
D 2026-01-02 2025-12-30 AGIO Jones Cecilia CFO M - OptEx $0.00 +6,000 40.3K +17% $0
D 2026-01-02 2025-12-30 AGIO Jones Cecilia CFO M - OptEx $0.00 -6,000 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common stock 2025-12-30 S D 2,932 $27.09 37,394 D — —
2 Common Common stock 2025-12-30 M A 6,000 $0.00 40,326 D — — (F1) Includes 456 shares purchased through the Company's employee stock purchase plan.
3 Derivative Performance share units 2025-12-30 M D 6,000 $0.00 0 D — · — to — 6,000 Common stock (F3) Each performance share unit represents a contingent right to receive one share of the issuer's common stock. (F4) The PSUs were granted on March 1, 2023. The PSUs vest as to 50% of the underlying shares upon the achievement of a specified research milestone and as to the remaining 50% of the underlying shares upon the achievement of a specified regulatory milestone. The performance criteria for the specified regulatory milestone was determined to have been met on December 29, 2025, resulting in the vesting of the PSUs as to 50% of the underlying shares. Vested shares will be delivered to the reporting person within three business days after such shares become vested.